▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] SK Biotek, a wholly owned drug-making subsidiary of SK Holdings, said on June 19 it will acquire US drug maker Bristol-Myers Squibb’s manufacturing plant in Ireland to enter the Europ...
[THE INVESTOR] For the past 11 years, South Korea has recorded the highest suicide rate among Organization for Economic Cooperation and Development countries, with depression and mental illnesses be...
[ THE INVESTOR ] Celltrion Healthcare said on June 16 new clinical data proved its biosimilar Truxima to be fully comparable to its reference medication, Roche’s Rituxan, in terms of efficacy and s...
[THE INVESTOR] Korea’s botulinum toxin maker Medytox has filed a civil lawsuit in the US against Daewoong Pharmaceutical and its US partner Alphaeon for allegedly stealing a key ingredient of its ...
[THE INVESTOR] Celltrion has started searching for a contract manufacturer in North America where it plans to launch two biosimilar products, local media outlet The Bell reported on June 15. “We ar...
[THE INVESTOR] A recent court ruling could advance the US launch of Samsung Bioepis’ Renflexis, biosimilar version of Johnson & Johnson’s blockbuster autoimmune monoclonal antibody treatment Remicad...
[THE INVESTOR] Medytox said on June 13 it has completed late-stage clinical trials for powder-type botulinum toxin in China to expand operations in the country. “China has high market potential fo...
[THE INVESTOR] Celltrion plans to submit biologics license applications for its copy versions of rituximab and trastuzumab to the US regulator over the next few months to begin sales in the US mark...
[ THE INVESTOR ] Medytox, Korea’s largest maker of botulinum toxin, said it has obtained regulatory approval for its new production plant in Osong, North Chungcheong Province. The Korean Ministry ...
[THE INVESTOR] Celltrion founder and chairman Seo Jung-jin will attend an investor roadshow next month ahead of the planned initial public offering of its marketing unit Celltrion Healthcare, the c...
[THE INVESTOR] The Korean government on June 9 decided not to offer insurance coverage for Pfizer’s new breast cancer drug Ibrance, questioning the pricey drug’s cost-effectiveness. The state-run c...
[ THE INVESTOR ] Korean pharmaceutical companies are poised to release a series of important drugs in the second half of this year, industry sources said on June 9. Kolon Life Science’s Invossa, a...
[ THE INVESTOR ] Samsung Bioepis, a biosimilar medicine affiliate of Samsung Group, said on June 8 it will break ground for the construction of a new headquarters near the current building in Song...
[ THE INVESTOR ] Korea’s biopharmaceutical firm Celltrion is pushing ahead with its clinical trial plans for a subcutaneous version of its biosimilar Remsima that will provide more convenient sel...
[ THE INVESTOR ] Celltrion said on June 5 its copy version of Roche’s Herceptin for patients with early breast cancer works as well as the original drug in late-stage trials. The drug, Herzuma, al...
[DECODED X] Chip off the shoulder
Samsung, SK hynix shares surge on rosy DRAM outlook
Samsung Bioepis’ Humira biosimilar gets approval in Korea
Tesla receives green light for gov’t subsidy in Korea
Analysts upbeat on Celltrion’s US market expansion
Versartis’ failed trials a boon for Genexine
Germany’s Delivery Hero acquires FoodFly
Toshiba to hold extraordinary shareholders meeting on Oct.24
![[DECODED X] Chip off the shoulder](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=152&simg=/content/image/2017/09/22/20170922000807_0.jpg&md=20170922170938)
